The Mirai capsule inhaler platform is a low resistance device that is intended for: 

• Traditional lactose blended formulations, including generic drugs for asthma and COPD (See our page on available APIs and test results.)

• NCEs for asthma and COPD

• NCEs for oncology

• Dry powder vaccines for inhalation

• Inhaled antibiotics

• Nutraceuticals

• Spray dried formulations